Hypoxia and angiogenesis in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 17, Issue 3, 2005, Pages 293-298

  Taylor, Peter C ^a,b   Sivakumar, Bran ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Hypoxia; Hypoxia inducible factor rheumatoid arthritis; Vascular endothelial growth factor

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; ENDOSTATIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INFLIXIMAB; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CELL NUCLEUS; COMORBIDITY; DISEASE ACTIVITY; ECHOGRAPHY; ENDOTHELIUM LESION; GENE ACTIVATION; GLYCOLYSIS; HUMAN; HYPOXIA; JOINT; NONHUMAN; PATHOGENESIS; PH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; TISSUE REACTION; VASCULAR DISEASE;

ANOXIA; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENDOTHELIUM, VASCULAR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 18144391498     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000155361.83990.5b     Document Type: Review

References (68)

1. Walsh DA. Angiogenesis and arthritis. Rheumatol 1999; 38:103-112.
2. Koch A. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl 2):ii60-ii67.
3. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36:127-137.
4. Mason JC, Lidington EA, Yarwood H, et al. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum 2001; 44:138-150.
5. Falchuk H, Goetzl J, Kulka P. Respiratory gases of synovial fluids. Am J Med 1970; 49:223-231.
6. Lund-Olesen K. Oxygen tension in synovial fluids. Arthritis Rheum 1970; 13:769-776.
7. Treuhaft PS, McCarty DJ. Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressures in various joint diseases. Arthritis Rheum 1971; 14:475-484.
8. 2 and hypoxia in inflammatory arthritis. Clin Exp Rheumatol 2002; 20:799-805.
9. Taylor PC, Miotla JM, Etherington P, et al. VEGF release is associated with hypoxia in inflammatory arthritis. Arthritis Rheum 2000; 43(Suppl 9):S296.
10. 2 tension. Proc Natl Acad Sci USA 1995; 92:5510-5514.
11. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-275.
12. Distler JH, Wenger RH, Gassmann M, et al. Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2004; 50:10-23. This excellent review summarizes current knowledge of the molecular signaling pathways that operate in response to hypoxia. Potential links between HIF-1 signaling pathways and the pathogenesis of RA are discussed.
13. Jiang BH, Semenza GL, Bauer C, et al. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996; 271:1172-1180.
14. Kallio PJ, Okamoto K, O'Brien S, et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1 alpha. EMBO J 1998; 17:6573-6586.
15. Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterisation and comparison with hypoxia-inducibie factor-1 alpha. Blood 1998; 92:2260-2268.
16. Thornton RD, Lane P, Borghaei RC, et al. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 2000; 350:307-312.
17. Stevens CR, Blake DR, Merry P, et al. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum 1991; 34:1508-1513.
18. Simonini G, Cerinic MM, Cimaz R, et al. Evidence for immune activation against oxidised lipoproteins in inactive phases of juvenile chronic arthritis. J Rheumatol 2001; 28:198-203.
19. Rowley D, Gutteridge JMC, Blake D, et al. Lipid peroxidation rheumatoid arthritis: thiobarbituric acid-reactive material and catalytic iron salts in synovial fluid from rheumatoid patients. Clin Sci 1984; 66:691-695.
20. Blake DR, Stevens CR, Sahinoglu T, et al. Xanthine oxidase: four roles for enzyme in rheumatoid pathology. Biochem Soc Trans 1997; 25:812-815.
21. Berse B, Hunt JA, Diegel RJ, et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999; 115:176-182.
22. Richard DE, Berra E, Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999; 266:718-722.
23. Hollander AP, Corke KP, Freemont AJ, et al. Expression of hypoxia-inducible factor 1α by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001; 44:1540-1544.
24. Giatromanolaki A, Sivridis E, Maltezos E, et al. Upregulated hypoxia inducible factor-1 alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003; 5:R193-R201.
25. Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthritis. Arthritis Res Ther 2004; 6:265-278. This excellent comprehensive review discusses the evidence for the role of oxidative stress and hypoxia in the pathogenesis of RA. The potential to exploit aspects of these pathways in novel therapeutic interventions is also discussed.
26. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1 alpha is essential for myeloid cell-mediated inflammation. Cell 2003; 112:645-657.
27. Hirohata S, Sakakibara J. Angioneogenesis as a possible elusive trigger factor in rheumatoid arthritis. Lancet 1999; 353:1331.
28. Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999; 103:3-4.
29. Storgard CM, Stupack DG, Jonczyk A, et al. Decreased angiogenesis and arthritic disease in rabbits treated with alphavbeta3 antagonist. J Clin Invest 1999; 103:47-54.
30. Taylor PC, Steuer A, Gruber J, et al. Measurement of synovitis and joint vascularity by ultrasonography in a randomised, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004; 50:1107-1116. This is the first study to successfully use ultrasonographic measures of synovial vascularity to assess outcome in the context of a placebo-controlled, double-blind, randomized study. It also shows that quantitative assessment of vascular signal in a defined set of joints in early RA is strongly predictive of the subsequent rate of structural damage as assessed by conventional radiography.
31. Ballara S, Taylor PC, Reusch P, et al. Serum vascular endothelial growth factor (VEGF) and soluble VEGF receptor in inflammatory arthritis. Arthritis Rheum 2001; 44:2055-2064.
32. Paleolog EM, Fava RA. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin Immunopathol 1998; 20:73-94.
33. Paleolog EM, Miotla JM. Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 1998; 2:295-307.
34. Jain A, Nanchahal J, Troeberg L, et al. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis Rheum 2001; 44:1754-1760.
35. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997; 79:233-269.
36. Achen MG, Stacker SA. The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int J Exp Pathol 1998; 79:255-265.
37. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.
38. Ikeda M, Hosoda Y, Hirose S, et al. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000; 191:426-433.
39. Pufe T, Petersen W, Tillmann B, et al. Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis. J Rheumatol 2001; 28:1482-1485.
40. Han SW, Kim GW, Seo JS, et al. VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:1173-1177. This paper explores relations between the clinical features of RA and four VEGF polymorphisms. The frequencies of two haplotypes were significantly increased in patients with RA compared with control participants, and carriers of the susceptible haplotypes had a younger age at disease onset but did not show a difference in the progression rate of radiographic joint destruction.
41. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180:341-346.
42. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152:4149-4156.
43. Kasama T, Shiozawa F, Kobayashi K, et al. Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts. Arthritis Rheum 2001; 44:2512-2524.
44. Cho CS, Cho ML, Min SY, et al. CD40 engagement on synovial fibroblast upregulates production of vascular endothelial growth factor. J Immunol 2000; 64:5055-5061.
45. Jackson JR, Minton JA, Ho ML, et al. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol 1997; 24:1253-1259.
46. Harada M, Mitsuyama K, Yoshida H, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27:377-380.
47. Kikuchi K, Kubo M, Kadono T, et al. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998; 139:1049-1051.
48. Bottomley MJ, Webb NJ, Watson CJ, et al. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol 1999; 117:171-176.
49. Nagashima M, Yoshino S, Ishiwata T, et al. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995; 22:1624-1630.
50. Taichman N, Young S, Cruchley A, et al. Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol 1997; 62:397-400.
51. Kasama T, Kobayashi K, Yajima N, et al. Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 121:533-538.
52. Nagashima M, Wauke K, Hirano D, et al. Effects of combinations of antirheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:1255-1262.
53. Lee SS, Joo YS, Kim WU, et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001; 19:321-324.
54. Sone H, Sakauchi M, Takahashi A, et al. Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci 2001; 69:1861-1869.
55. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41:1258-1265.
56. Kucharz EJ, Gozdzik J, Kopec M, et al. A single infusion of infliximab increases the serum endostatin level in patients with rheumatoid arthritis. Clin Exp Rheumatol 2003; 21:273-274.
57. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226:324-328.
58. Hornig C, Weich HA: Soluble VEGF receptors. Recombinant and naturally occurring forms involved in the regulation of angiogenesis. Angiogenesis 1999; 3:33-39.
59. Taylor PC, Patel S, Paleolog E, et al. Reduced synovial vascularity following TNFα blockade in rheumatoid arthritis. Arthritis Rheum 1998; 41:s295.
60. Taylor PC: Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford) (In press).
61. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004; 6:R326-R334.
62. Canete JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004; 50:1636-1641.
63. Vaudo G, Marchesi S, Gerli R, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63:31-35. This study reports altered endothelial reactivity, as evidenced by reduced brachial vasodilatation, in patients with RA, including those with low disease activity and with no traditional cardiovascular risk factors and no overt cardiac disease.
64. Hansel S, Lassig G, Pistrosch F, et al. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003; 170:177-180.
65. Bergholm R, Leirisalo-Repo M, Vehkavaara S, et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002; 22:1637-1641.
66. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44:2737-2746.
67. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106:2184-2187.
68. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51:447-450. The authors demonstrate that TNFα blockade with infliximab has a transient favorable effect on endothelial-dependent, but not endothelial-independent, vasodilation as assessed by noninvasive brachial ultrasonography. All patients had been treated with infliximab for at least 1 year before the study. It is not yet clear whether such transient restoration of endothelial homeostasis actually retards the clinical progression of atherosclerosis in patients with RA.